Immuneering Corporation (NASDAQ: IMRX) reported first quarter 2026 financial results and provided updates on its clinical programs, according to a company statement.

The oncology company ended the quarter with $198.6 million in cash, cash equivalents and marketable securities, compared to $217.0 million at the end of 2025. The company expects this cash position to fund operations into 2029.

For the first quarter, Immuneering reported a net loss of $13.5 million, or $0.21 per share, compared to a net loss of $15.0 million, or $0.42 per share, in the same period last year. Research and development expenses decreased to $10.6 million from $11.5 million year-over-year, while general and administrative expenses increased to $4.7 million from $4.0 million.

The company announced that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel will be presented at the 2026 ASCO Annual Meeting on June 1. The presentation will use data with an April 2026 cutoff.

Immuneering's pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus modified gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic cancer is now recruiting patients. The company remains on track to dose the first patient by mid-2026.

The company also reported on a third-line pancreatic cancer patient who has been receiving atebimetinib monotherapy for 27 months, showing an 85% reduction in tumor burden with complete resolution of four lesions. The patient has gained 23 pounds during treatment and reported improved quality of life with no grade 3 adverse events.

Immuneering plans to dose the first patient in its Phase 2 lung cancer trial of atebimetinib plus Libtayo in RAS-mutant first-line non-small cell lung cancer in the second half of 2026.